Janux Therapeutics JANX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's accrued expenses?
- Janux Therapeutics (JANX) reported accrued expenses of $15.48M in Q1 2026.
- How has Janux Therapeutics's accrued expenses changed year-over-year?
- Janux Therapeutics's accrued expenses increased by 16.0% year-over-year, from $13.34M to $15.48M.
- What is the long-term trend for Janux Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Janux Therapeutics's accrued expenses has grown at a 88.0% compound annual growth rate (CAGR), from $751K to $17.63M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.